Skip to main content
Clinical Trials/NCT05533060
NCT05533060
Recruiting
Not Applicable

Clinical and Molecular Biological Data Collection and Analysis in Patients With Traumatic Brain Injury (TBI)

Shanghai 6th People's Hospital1 site in 1 country200 target enrollmentSeptember 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Traumatic Brain Injury
Sponsor
Shanghai 6th People's Hospital
Enrollment
200
Locations
1
Primary Endpoint
Accurate assessment of patients' neurological condition
Status
Recruiting
Last Updated
12 months ago

Overview

Brief Summary

Clinical evaluation is crucial in the clinical diagnosis, treatment, and prognosis prediction in patients with traumatic brain injury (TBI). However, the existing evaluation systems are not perfect, because many factors are not taken into account, for example, there is a lack of molecular diagnostic criteria for evaluating patients with TBI. We attempt to collect the patient's clinical data and combine it with neuroimaging, as well as molecular biomarkers generated by single-cell sequencing to assess their neurological status and outcome. The clinical and molecular data collection and analysis will be helpful to evaluate the patient's neurological condition and predict the patient's outcome more accurately.

Detailed Description

Specifically, eligible patients will be treated surgically. In one group, injured brain tissue removed during decompression and resection will be preserved in a tissue preservation solution. In another group, brain tissue in the surgical trajectory during surgical resection of the brain lesion (for example, gliomas, meningiomas, schwannomas) will be also preserved in the solution. Then these tissues will be analyzed through high-throughput single-cell sequencing and bioinformatics analysis. In order to obtain the most changed biomarkers, we will pick up the top 10 cell subgroups with 10 expression biomarkers in each subgroup to compare them with the results analyzed in the mice brain tissue. The target biomarkers will be validated in the cerebrospinal fluid (CSF) and blood in patients with TBI for the patient's neurological status evaluation and outcome prediction. At the same time, the patient's pre- and postoperative clinical data (including, gender, age, GCS score, pupil light reflection, CT results, etc) will also be collected. A regression model will be generated to estimate the relationship between the patient's neurological status and these independent variables. In addition, the association between a patient's prognosis and these factors will also be analyzed. ROC curve will be used to compare our regression model to the established GCS score scale and Marshall CT grading.

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
December 30, 2027
Last Updated
12 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hao Chen, MD, PhD

Associate Clinical Professor, Supervisor

Shanghai 6th People's Hospital

Eligibility Criteria

Inclusion Criteria

  • CT/MRI confirmed TBI;
  • The time from onset to the emergency room (ER ) within 12h;
  • The systolic pressure (SBP) ≥ 90 mmHg;
  • Patients willing to participate in this study with signed informed consent.

Exclusion Criteria

  • Patients who are not suitable for surgery (GCS score 3 points, dilated and fixed bilateral pupils, pregnant women, etc.);
  • Pre-injury life expectancy ≤ 1 year (malignant tumor);
  • Previous history of acute myocardial infarction, abnormal immune function, and blood-related diseases;
  • without informed consent.

Outcomes

Primary Outcomes

Accurate assessment of patients' neurological condition

Time Frame: 2022.09-2023.12

Using a regression model to explore the relationship between a patient's neurological condition and clinical and molecular biological data

Secondary Outcomes

  • Predicting patients' outcome accurately(2022.09-2023.12)

Study Sites (1)

Loading locations...

Similar Trials